生物制药公司硕迪生物近日在纳斯达克挂牌上市，募资额约为1.61亿美元，成为最近数月以来规模最大的生物科技美国上市项目。中伦律师事务所、美国科律律师事务所为发行人律师；君合律师事务所、瑞生国际律师事务所则为承销商提供法律服务。

硕迪生物是一家处于临床阶段的全球生物医药企业，致力于开发应用新型口服疗法，以治疗各类尚无对症的慢性疾病；其初期重点是将G蛋白偶联受体作为治疗靶点系列。

科律团队由全球资本市场业务联席负责人、合伙人Charlie Kim、合伙人陆培祥(Patrick Loofbourrow)、合伙人Andrew Harline领衔。

中伦团队由合伙人赵靖和贾海波牵头。

君合团队由合伙人叶宇嵘和陈燕领衔。

瑞生团队由合伙人Matt Bush以及Cheston Larson领导。

该项目中的联席承销商为富瑞、硅谷银行证券、古根海姆证券和蒙特利尔银行资本市场。

Cooley, Latham & Watkins led China biotech startup back to the U.S. cap mkt

Cooley and Zhong Lun Law Firm have advised biotech company Structure Therapeutics Inc. on its $161 million IPO on the Nasdaq Global Market, with JunHe and Latham & Watkins advising the joint sponsors.

Cooley addressed in a press release that this transaction is the largest biotech U.S. IPO in recent months.

Structure Therapeutics is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its initial focus is on G-protein-coupled receptors as a therapeutic target class.

The Cooley team was led by partners Charlie Kim, Patrick Loofbourrow and Andrew Harline.

The Zhong Lun team was led by partners Anthony Zhao and William Jia.

The JunHe team was led by partners Ye Yurong and Chen Yan.

The Latham team was led by partners Matt Bush and Cheston Larson.

The joint sponsors included Jefferies, SVB Securities, Guggenheim Securities and BMO Capital Markets.